Accessibility StatementSkip Navigation SHANGHAI, Sept. 21, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, implemented its first interim dividend plan, distributing a total of RMB1.03 billion in cash dividends. Also from this source WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability Rating for Second Consecutive Year WuX ...

Group 1 - Leading photovoltaic company GCL-Poly announced a strategic investment of approximately $700 million from international investment firm Wujin Capital, backed by a Middle Eastern sovereign fund [1] - Weimob Group also secured a $200 million subscription from Wujin Capital shortly after GCL-Poly's announcement, indicating a trend of international capital targeting Chinese industry leaders [1] - The participation of international capital in refinancing through methods like private placements and rights issues reflects a long-term investment perspective, emphasizing confidence in the fundamentals and growth potential of Chinese companies [1] Group 2 - The continuously optimized foreign investment policy environment in China supports international capital's participation in domestic company refinancing [2] - Recent policies, including the "Management Measures for Strategic Investment by Foreign Investors in Listed Companies," encourage long-term and value investments from foreign capital [2] - The State Administration of Foreign Exchange has issued guidelines to enhance the convenience of cross-border investment and financing, further facilitating foreign investment in China [2][3] Group 3 - The rapid development of China's technological innovation is reshaping international capital's perception of the Chinese economy, moving beyond the view of China as merely a "world factory" [4] - China's R&D investment is projected to exceed 3.6 trillion yuan in 2024, a 48% increase from 2020, with a research intensity surpassing the average of EU countries [4] - The number of high-tech enterprises in China has increased by 83% since 2020, indicating a robust growth in innovation capabilities [4] Group 4 - Significant achievements in various fields such as quantum technology and life sciences have positioned China as a global leader in innovation, with the country ranking 10th in comprehensive innovation capability by 2024 [4] - The pharmaceutical sector has seen substantial growth, with nearly $66 billion in licensing deals for innovative drugs in the first half of 2025, showcasing the potential for revenue generation [5] - In the humanoid robotics sector, over 83 projects have been disclosed in the first half of 2025, with contract amounts totaling nearly 330 million yuan, indicating a strong market demand and performance [5] Group 5 - International capital is transitioning from being mere financial investors to strategic partners, actively engaging in governance, technology collaboration, and market expansion for Chinese companies [5] - As China's capital market continues to open up, international capital is expected to increasingly invest in innovative technology firms, sharing in the growth and development benefits [5]

Core Points - The company announced a cash dividend of RMB 0.35000 per share (including tax) for the first half of 2025, totaling RMB 1,033,027,357.60 (including tax) to be distributed among A-share shareholders [2][4] - The distribution plan was approved by the board of directors on July 28, 2025, following authorization from the annual general meeting held on April 29, 2025 [2][3] Distribution Plan - The dividend will be distributed to all A-share shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [3] - The total number of shares for the dividend calculation is 2,951,506,736 shares, with A-shares receiving a total of RMB 865,648,086.10 (including tax) [4] Taxation Details - For individual A-share shareholders, the cash dividend will not be subject to withholding personal income tax at the time of distribution. The actual amount received will be RMB 0.35000 per share [6] - Qualified Foreign Institutional Investors (QFII) will have a 10% corporate income tax withheld, resulting in an actual distribution of RMB 0.31500 per share [7] - Hong Kong investors through the Stock Connect will also face a 10% withholding tax, leading to an effective dividend of RMB 0.31500 per share [8] - Other institutional investors and corporate shareholders will receive the full amount of RMB 0.35000 per share without tax withholding [9]

Group 1 - The global liquidity environment is becoming more accommodative, leading to a significant inflow of international capital into the Hong Kong market, particularly in the biotech sector [1][2] - As of September 12, 2025, southbound capital from mainland China has net purchased over 10,000 billion HKD in Hong Kong stocks this year, representing a growth of over 100% compared to last year, with the biotech sector attracting 1613 billion HKD [1] - The implementation of Chapter 18A of the Hong Kong Stock Exchange's main board listing rules since 2018 has allowed unprofitable biotech companies to enter the capital market, raising over 800 billion HKD and establishing Hong Kong as a major biotech financing hub [1] Group 2 - In 2025, national policies have been introduced to support the biotech industry, emphasizing innovation and significantly shortening the drug approval process, with IND and NDA approvals increasing by 14.3% and 52.3% respectively in 2024 [2] - The shift in healthcare insurance policies towards supporting innovative drugs has opened new payment channels for high-value drugs, enhancing their market accessibility [2] - A comprehensive policy framework is being established to support the entire lifecycle of innovative drugs from development to market sales, creating sustained growth opportunities for companies and investors [2] Group 3 - The Hang Seng Biotech Index, launched in December 2019, focuses on innovative drugs and contract research organizations (CROs), with nearly 90% of its weight in these sectors, showcasing top industry players [3] - The index has demonstrated exceptional growth and resilience, with a year-to-date increase of over 100% as of early September 2025, significantly outperforming the Hang Seng Index's 27% increase [3] - Despite recent market adjustments, the index's valuation remains relatively low at a price-to-earnings ratio of approximately 31 times, providing substantial room for future valuation recovery and earnings growth [3] Group 4 - The Hong Kong Stock Connect Biotech ETF (159102) offers investors a convenient tool to invest in the biotech sector, with liquidity advantages and no restrictions from QDII quotas [4] - The ETF allows for T+0 trading, enhancing its appeal for investors looking to capitalize on opportunities in the Hong Kong biotech market [4]

Group 1 - The core point of the article is that WuXi AppTec announced its cash dividend distribution plan for the first half of 2025, which is set at 0.35 yuan per share (tax included) [1] - The record date for the dividend distribution is September 25, 2025, and both the ex-dividend date and the cash dividend payment date are September 26, 2025 [1]

（於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年9月19日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2025-063 无锡药明康德新药开发股份有限公司 2025年半年度A 股权益分派实施公告 本公司董事会及全体董事保证本公告内容不存 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-063 A 股每股现金红利0.35000元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/9/25 | － | 2025/9/26 | 2025/9/26 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经无锡药明康德新药开发股份有限公司（以下简称"本公 司"） 2025 年 4 月 29 日的2024年年度股东大会授权董事会在符合利润分配的条件 下制定具体的中期分红方案，并经 2025 年 7 月 28 日召开的第三届董事会第二十 二次会议审议通过。 无锡药明康德新药开发股份有限公司 2025年半年度A 股权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放 ...

Core Viewpoint - The significant stock price movements in A-shares on September 19 were primarily driven by the adjustments in the FTSE China A50 Index, which took effect after the market closed on that day [1][6]. Group 1: Stock Movements - Several stocks, including Xinyi Technology, Zhongji Xuchuang, WuXi AppTec, and BeiGene, experienced notable price increases during the closing auction period [2][1]. - Conversely, stocks such as China Nuclear Power, China Unicom, and Wanhua Chemical saw substantial declines, with China Nuclear Power dropping nearly 2 percentage points [4][1]. Group 2: Index Adjustments - The FTSE Russell announced changes to the FTSE China A50 Index, which included the addition of stocks like Xinyi Technology and WuXi AppTec, while removing China Nuclear Power and China Unicom [6][1]. - The FTSE China A50 Index consists of the 50 largest stocks listed on the Shanghai and Shenzhen exchanges and undergoes quarterly reviews [6][1]. Group 3: Market Reactions - The adjustments in the FTSE indices prompted index funds and institutional investors to rebalance their portfolios, leading to the observed stock price volatility [1][6]. - The market showed a clear divergence in performance, with sectors like photolithography, lithium mining, and engineering machinery gaining strength, while others faced significant corrections [2][1]. Group 4: Broader Market Context - The overall A-share market experienced a mixed performance, with the Shanghai Composite Index down by 0.30% and the Shenzhen Component down by 0.04% [2][1]. - In the Hong Kong market, stocks such as Fourth Paradigm and SF Holding also exhibited significant movements, influenced by similar index adjustments [7][1]. Group 5: Future Outlook - Analysts suggest that the Chinese stock market may see further prosperity driven by valuation and liquidity factors, maintaining a positive outlook on both A-shares and H-shares [7][8]. - Focus areas include core growth sectors in Hong Kong, particularly in internet, innovative pharmaceuticals, new consumption, and technology [8][1].

无锡药明康德新药开发股份有限公司发布2025年半年度A股权益分派实施公告。本次利润分配方案经 2024年年度股东大会授权及第三届董事会第二十二次会议审议通过。以总股本2,951,506,736股为基数， 每股派发现金红利0.35元（含税），A股共派发现金红利865,648,086.10元（含税）。股权登记日为2025 年9月25日，除权（息）日和现金红利发放日为9月26日。不同类型股东扣税政策有别，如自然人股东和 证券投资基金暂不扣缴，QFII股东和沪股通投资者按10%税率代扣。如有疑问可联系董事会办公室，电 话021 - 20663091。 ...

Group 1 - The core point of the article highlights significant stock movements in the A-share market, with several companies experiencing sharp fluctuations during the closing auction [1] - New companies such as Baijiazhenshou-U, New Yisheng, WuXi AppTec, and Zhongji Xuchuang are being added to the FTSE China A50 Index, while companies like China Nuclear Power, China Unicom, Guodian Nari, and Wanhua Chemical are being removed [1] - The changes announced by FTSE Russell on September 3 will take effect after the market closes on September 19 [1]